Abstracts 11 indirect comparisons). All the results were obtained from indirect comparison. Dutasteride, compared to finasteride, significantly improved AUA-SI score (WMD = 1.53), and influenced PSA concentration (WMD = −1.33). Average costs (including drugs costs, complications and prostatic cancer treatment) and effects (LY with no surgery/prostatic cancer) were per patient: dutasteride 5655 PLN/6.23 LY; finasteride 6081 PLN/5.13 LY. Dutasteride was dominant therapy compared with finasteride (more effective and less costly). CONCLUSIONS: Dutasteride is clinically more effective and more cost-effective in BPH compared to both placebo and finasteride.
Del Angel-García G 1 , Garcia-Contreras F 2 , Constantino-Casas P 2 , Nevarez-Sida A 2 , Lopez-Gonzalez N 3 , García-Constantino M 1 , Zuñiga M 3 1 Instituto Mexicano del Seguro Social, México City, Mexico City, Mexico, 2 Mexican Institute of Social Security, México, Distrito Federal, Mexico, 3 Mexican Institute of Social Security, México City, Mexico City, Mexico OBJECTIVE: To evaluate the cost-effectiveness of IMSS formulary drugs for preventing uterine atony in patients with risk factors. METHODS: A final report of a randomized pragmatic clinical trial at the Mexican Institute of Social Security (IMSS) is presented. Carbetocine and oxytocin are the only drugs within IMSS formulary for preventing uterine atony. Risk factor included fetal macrosomia, polyhydramnios, low insertion of the placenta, multiple gestation, prolonged labor, uterine myomas and chorioamnionitis. The effectiveness was defined as the reduction of the number of patients with uterine atony. The use of resources was obtained from the clinical trial and the costs were gotten from financial information from IMSS, and are expressed in US 2006 dollars. Squared ji and U de Mann Whitney test were used. Univariate and probabilistic sensitivity analyses, a Monte Carlo microsimulation with 10,000 iterations was performed using probability distribution data from the clinical trial. A 95% confidence interval of ICER was calculated by ellipse method. RESULTS: Seventy-seven patients received carbetocine and 75 oxytocin. Both groups had similar obstetrics and sociodemographic characteristics. Uterine atony was reported in 19% in the oxytocin group compared to 8% in the carbetocine one (p < 0.0001). Multiple gestation was the most frequent diagnosis, 35% (p < 0.0001). Bleeding was less than 500 mL in the carbetocine group and 500-1000 mL in the oxytocin one (p < 0.0001). Mean cost per patient treated with carbetocine was $3525 vs. $4054 for oxytocine (p < 0.0001). Mean cost-effectiveness ratio for oxytocin was $4944, while for carbetocine $3874; ICER showed that carbetocine was dominant. Univariate analysis supported those results. The acceptability curve and health net benefits showed that carbetocine group was superior independently of WTP. CI 99% by ellipse method showed that carbetocine was dominant in 100% of cases. CONCLUSIONS: Carbetocine was dominant in preventing uterine atony in patients with risk factors. As part of a health technology assessment comparing a single-embryo-transfer (SET) in In-Vitro Fertilization (IVF) with the traditional double-embryo-transfer (DET) used today in Denmark the cost-effectiveness of SET was compared with DET. The aim was to inform decision-makers about the economic consequences of the eventual adoption of a SET policy in Denmark. METHODS: The analysis was based on prospective collection of resource use and costs of singletons and twins. A total of 213 pregnant women at the fertility clinic have been reporting resource use (health care and so-cial sector), and days absent from work in cost diaries during a year (from pregnancy scan to until three months after delivery). Clinical effectiveness data of SET and DET came from a Scandinavian multi-center trial, and a recent Cochrane review. RESULTS: The advantage of SET is delivery of few expensive twins compared with DET (25%). The cost-effectiveness per clinical pregnancy of DET (DKK 115,321 per clinical pregnancy and DKK 120,934 per delivery) was lower than using that of SET (DKK 131,446 per clinical pregnancy and DKK 149,833 per delivery). The costeffectiveness of DET is explained by a higher clinical pregnancy rate, a higher rate of delivery, and more children born. However, DET is also a more expen-sive alternative for the average patient treated, because of higher costs for delivery and neonatal care. The extra cost per patient using DET is around DKK 82,000 per delivery and around DKK 50,000 per extra child born using DET. CONCLUSION: The cost per delivery and per child born is lower using DET compared with SER. However, the total costs for DET is higher due to higher antenatal, delivery and neonatal costs, as well as production loss. A higher rate of twin deliveries using DET explains this. These extra costs using the more effective DET policy are moderate.
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PROPORTION OF HERPES ZOSTER (HZ) PATIENTS DEVELOPING POST-HERPETIC NEURALGIA (PHN) AND ITS MANAGEMENT IN THE UK
Gauthier A 1 , Remy V 2 , Martin M 1 , Pedalino B 2 1 i3 Innovus, Uxbridge, Middlesex, UK, 2 Sanofi Pasteur MSD, Lyon, France Quantitative information on the management of PHN, a complication of HZ, is scarce, with the most recent data from 1975. With the imminent arrival of a prophylactic Zoster vaccine, it is important to document the burden of PHN in the UK. OBJEC-TIVES: To estimate the proportion of HZ patients developing PHN, the duration, resource use and costs of PHN sufferers, using two definitions: pain persisting one (1-month definition) or three months (3-month definition) after HZ onset. METHODS: Records of immuno-competent individuals of ≥50 years, diagnosed with HZ between 2000 and 2005, and with ≥1-year follow-up were selected from the UK General Practice Research Database (GPRD). PHN episodes were identified by formal diagnosis and prescriptions of typical neuropathic pain medications.
